Sugi Predict

Sugi Predict / Compounds / SCHEMBL61034

SCHEMBL61034

SCHEMBL61034

CC(C)(C)OC(=O)CCCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)ON1C(=O)CCC1=O)C(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 8/20 0.43
▸ HPGD P15428 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ TLR2 O60603 1/20 0.36
▸ TLR1 Q15399 1/20 0.36
▸ GLO1 Q04760 1/20 0.34
▸ BCHE P06276 1/20 0.34
▸ ACHE P22303 1/20 0.34
▸ KMT2A Q03164 2/20 0.33
▸ PLK1 P53350 1/20 0.33
▸ ADORA1 P30542 1/20 0.32
▸ CCKAR P32238 1/20 0.31
▸ CCKBR P32239 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1895784 1.00 GLP1R (0.43) GLP1RHPGDHTTSMN1; SMN2TLR2
SCHEMBL25162403 1.00 GLP1R (0.43) GLP1RHPGDHTTSMN1; SMN2TLR2
SCHEMBL2159690 1.00 GLP1R (0.43) GLP1RHPGDHTTSMN1; SMN2TLR2
SCHEMBL18379134 1.00 GLP1R (0.43) GLP1RHPGDHTTSMN1; SMN2TLR2
SCHEMBL20608161 1.00 GLP1R (0.43) GLP1RHPGDHTTSMN1; SMN2TLR2
SCHEMBL24486698 0.97 GLP1R (0.41) GLP1RHPGDHTTSMN1; SMN2TLR2
SCHEMBL19034919 0.97 GLP1R (0.41) GLP1RHPGDHTTSMN1; SMN2TLR2
SCHEMBL3435333 0.94 GLP1R (0.46) GLP1RHPGDHTTSMN1; SMN2TLR2
SCHEMBL30118291 0.94 GLP1R (0.50) GLP1RHPGDHTTSMN1; SMN2BCHE
SCHEMBL29414972 0.93 GLP1R (0.49) GLP1RHPGDHTTSMN1; SMN2BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042809-A1 PROCESS FOR THE PREPARATION OF SEMAGLUTIDE MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2026-02-12 — — US disclosed
EP-4380962-A1 PROCESS FOR THE PREPARATION OF SEMAGLUTIDE MSN Laboratories Private Limited, R&D Center (IN) 2024-06-12 — — EP disclosed
WO-2023012829-A1 PROCESS FOR THE PREPARATION OF SEMAGLUTIDE MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) 2023-02-09 — — WO disclosed
CN-113754753-A Synthetic method of somaglutide 深圳翰宇药业股份有限公司 2021-12-07 — — CN disclosed
US-20190112348-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES NOVO NORDISK AS (DK) 2019-04-18 — — US disclosed
US-10259856-B2 Protease stabilized acylated insulin analogues NOVO NORDISK A/S (DK) 2019-04-16 — — US disclosed
EP-2238153-B1 SEMI-RECOMBINANT PREPARATION OF GLP-1 ANALOGUES NOVO NORDISK AS (DK) 2019-02-20 — — EP disclosed
US-9732137-B2 Semi-recombinant preparation of GLP-1 analogues NOVO NORDISK A/S (DK) 2017-08-15 — — US disclosed
US-9688737-B2 Protease stabilized acylated insulin analogues NOVO NORDISK A/S (DK) 2017-06-27 — — US disclosed
EP-2910570-B1 Protease stabilized, acylated insulin analogues NOVO NORDISK AS (DK) 2016-10-12 — — EP disclosed
US-20110105720-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES NOVO NORDISK A/S (DK) 2011-05-05 — — US disclosed
US-20110098439-A1 INSULINS WITH AN ACYL MOIETY COMPRISING REPEATING UNITS OF ALKYLENE GLYCOL CONTAINING AMINO ACIDS NOVO NORDISK A/S (DK) 2011-04-28 — — US disclosed
US-20110098440-A1 Insulin Analogues with an Acyl and Alkylene Glycol Moiety NOVO NORDISK A/S (DK) 2011-04-28 — — US disclosed
US-20100317057-A1 SEMI-RECOMBINANT PREPARATION OF GLP-1 ANALOGUES NOVO NORDISK A/S (DK) 2010-12-16 — — US disclosed
EP-2254906-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES Novo Nordisk A/S (DK) 2010-12-01 — — EP disclosed
EP-1863839-B1 ACYLATED GLP-1 COMPOUNDS NOVO NORDISK AS (DK) 2010-08-04 — — EP disclosed
WO-2009115469-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES NOVO NORDISK A/S (DK) 2009-09-24 — — WO disclosed
US-20090156478-A1 Acylated GLP-1 Compounds NOVO NORDISK A/S (DK) 2009-06-18 — — US disclosed
EP-1863839-A2 ACYLATED GLP-1 COMPOUNDS NOVO NORDISK A/S (DK) 2007-12-12 — — EP disclosed
WO-2006097537-A2 ACYLATED GLP-1 COMPOUNDS NOVO NORDISK A/S (DK) 2006-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105720-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES IAPP, IDE, LIPE GLP1R 84/4885HPGD 3283/4885HTT 805/4885
US-20090156478-A1 Acylated GLP-1 Compounds GLP1R, GIPR, GCGR GLP1R 1/4885HPGD 2687/4885HTT 459/4885
US-20110098440-A1 Insulin Analogues with an Acyl and Alkylene Glycol Moiety IAPP, INSR, IGF1R GLP1R 7/4885HPGD 3290/4885HTT 1804/4885
US-20110098439-A1 INSULINS WITH AN ACYL MOIETY COMPRISING REPEATING UNITS OF ALKYLENE GLYCOL CONTAINING AMINO ACIDS IAPP, INSR, IGF1R GLP1R 19/4885HPGD 3971/4885HTT 1040/4885
US-20260042809-A1 PROCESS FOR THE PREPARATION OF SEMAGLUTIDE GCG, GLP1R, MET GLP1R 2/4885HPGD 4163/4885HTT 1060/4885
US-20190112348-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES IAPP, IDE, LIPE GLP1R 84/4885HPGD 3283/4885HTT 805/4885
US-10259856-B2 Protease stabilized acylated insulin analogues IAPP, IDE, LIPE GLP1R 54/4885HPGD 3295/4885HTT 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.